Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,494 active trials253 approved drugs3,567 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics477
Variants & evidence3567
Drugs398
Trials92594
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,275)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,776–3,800 of 4,275 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
· Clin Cancer Res · 2015 · PMID 26015511 · validated civic_curation pubmed
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
· Br J Cancer · 2011 · PMID 21119661 · validated civic_curation pubmed
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
· PLoS One · 2015 · PMID 26267899 · validated civic_curation pubmed
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed
Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
· J Oral Pathol Med · 2016 · PMID 25677871 · validated civic_curation pubmed
Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.
· Br J Cancer · 2015 · PMID 26291055 · validated civic_curation pubmed
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
· Oncotarget · 2016 · PMID 26745678 · validated civic_curation pubmed

Showing 3,776–3,800 of 4,275 publications

← Previous
1
…
151
152
153
…
171
Next →

Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.

· Mol Cancer Ther · 2014 · PMID 24356815 · validated civic_curation pubmed

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.

· Oncotarget · 2014 · PMID 25587029 · validated civic_curation pubmed

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

· Oncotarget · 2014 · PMID 25216528 · validated civic_curation pubmed

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

· Cell Death Dis · 2014 · PMID 25210794 · validated civic_curation pubmed

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

· Cell Cycle · 2015 · PMID 25590338 · validated civic_curation pubmed

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

· Cell Death Differ · 2014 · PMID 24013721 · validated civic_curation pubmed

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.

· J Clin Invest · 2013 · PMID 23867504 · validated civic_curation pubmed

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

· Clin Cancer Res · 2012 · PMID 22623731 · validated civic_curation pubmed

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

· Oncogene · 2011 · PMID 20956938 · validated civic_curation pubmed

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

· Cancer Res · 2008 · PMID 18593940 · validated civic_curation pubmed

MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.

· Mol Cancer Ther · 2008 · PMID 18445659 · validated civic_curation pubmed

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

· Cancer Discov · 2014 · PMID 24893891 · validated civic_curation pubmed

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

· PLoS One · 2016 · PMID 26821351 · validated civic_curation pubmed

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

· J Clin Invest · 2011 · PMID 21985784 · validated civic_curation pubmed

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

· Oncogene · 2005 · PMID 16091755 · validated civic_curation pubmed

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

· Nat Med · 2013 · PMID 24162815 · validated civic_curation pubmed

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

· Nat Med · 2006 · PMID 16341243 · validated civic_curation pubmed

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

· Blood · 2013 · PMID 23430109 · validated civic_curation pubmed